Senior Director, Translational Medicine

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, all currently in clinical development.

About the role

The Translational Medicine team at Revolution Medicines is seeking a highly motivated, scientifically creative, and collaborative Senior Director to lead the design and execution of clinical biomarker plans for RAS(ON) inhibitor clinical programs across solid cancer types. This role will report to the Head of Clinical Biomarker Development and serve as a subject-matter expert in clinical biomarker development, supporting clinical development strategy and programs through the product life cycle.

Responsibilities

• Lead strategic, translational thinking and contributions to early and late-stage clinical development plans.
• Represent the Translational Medicine function on cross-functional teams at the program level.
• Collaborate with Clinical Development, Clinical Operations, Biostatistics, Biomarker Operations, and Regulatory on study design and protocol development.
• Partner with Clinical Bioinformaticians in developing biomarker analysis plans and collaborate with Translational Medicine subfunctions, including Clinical Biomarker Operations, Clinical Bioinformatics, and Companion Diagnostics.
• Collaborate with Clinical Development, Biostatistics, and Medical Affairs to develop plans for publication of clinical biomarker results.
• Collaborate with Cancer Biology, Translational Research, and Cancer Immunology to accelerate forward and reverse translational research.
• Stay abreast of new developments in RAS biology, predictive biomarkers, and novel molecular assays, and share knowledge with functional and cross-functional team members.

Requirements

• Ph.D. in cancer biology, cell/molecular biology, genomics, or equivalent with 10+ years of industry experience.
• 6+ years of experience in clinical biomarker development in oncology.
• Development experience within oncogenic signaling pathways.
• Broad knowledge and understanding of established and novel technologies employed in clinical diagnostic assays (e.g., NGS, IHC, PCR).
• Broad knowledge of utilizing local enrollment strategies for biomarker identification of patients.
• Excellent scientific and business communication skills, strong interpersonal and collaboration skills, and planning skills.
• Ability to think critically and creatively, and work independently to determine appropriate resources for problem resolution.
• Ability to multi-task and thrive in a fast-paced, innovative environment.
• Commitment to Revolution Medicines’ Core Values: Tireless Commitment to Patients, Transformative Science, Exceptional Together, Total Integrity, Inclusiveness and Fairness.

Preferred Skills

• Knowledge of RAS biology and mechanism of action of RAS inhibitors.
• Prior experience within RAS-MAPK clinical development.
• Development experience across Phase 1 and Phase 3 clinical trials.

Pay

The base pay salary range for this full-time position for candidates working onsite at the headquarters in Redwood City, CA is $244,000 - $305,000 USD. The range may be adjusted for the local market where a candidate is based. Individual base pay salary is determined by job-related skills, experience, market dynamics, and relevant education or training.

Benefits

Revolution Medicines offers competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities as part of its total rewards program.